$ME->Wakeup('2021-02-15 00:00:00');
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are "at bat" in the major leagues... the NIH trial data will be used confirm efficacy. Just a waiting game.
Best,
JB
Bravo sir!
Best,
JB
"Did we just become best friends"
-StepBrothers
Dr. Patrice P. Jean is the Chair of the Life Sciences Practice at Hughes Hubbard & Reed, an international law firm based in New York City. She has over a decade of experience counselling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law, including asserting and defending patent rights underlying core technologies and innovations. Dr. Jean graduated summa cum laude from Xavier University of Louisiana in 1993 with a degree in biochemistry, and she holds a Ph.D. in molecular biology from Princeton University. She graduated from Columbia University School of Law in 2002, where she was Editor-in-Chief of the Columbia Science & Technology Law Review. Dr. Jean currently serves as Vice-President of the New York Intellectual Property Law Education Foundation and is a Board member of the New York Intellectual Property Law Association.
We will be just fine....
With the amount of RLF news and a reinstatement - the RLFTF intro is going to be updated! There is A LOT to add, its going to take a bit. Going to add all of past study links for other conditions from mc & others posts too
Best,
JB
'Meme stock' rally pauses, Redditors focus on biotech stocks
https://www.reuters.com/article/usa-stocks-meme/meme-stock-rally-pauses-redditors-focus-on-biotech-stocks-idUSL3N2NW1FK
Patience....
Best,
JB
Nothing better to do than post about a stock you think is not going to increase? If that's how you feel, you might want to sell and move on. What is the motivation to spew your "FEELINGS" and "CONCERNS" all day every day? Why are you here? If you do not feel it will go up, sell ... it's that simple. If you think the management is terrible, sell... quite easy to do. If you think some nefarious activities are taking place, sell... just as easily as you bought.
Please explain why dafuq are you still even here?!?!?!
Relief acquired the India patent by merging with Therametrics in 2016. The India patent expired in 2017 while Gaël Hédou was the CEO of Relief at that time. Gaël Hédou remained as the RLF CEO until June 2019.
He has been the Sonnet CEO since August 2019.
This is who was in charge at the time the patent in India expired, I am glad he has not been part of RLF management for over 2 years now.
Best,
JB
Correction: Well we HAD a patent in India :)
Patent 246915 expired on 07/03/2017
https://ipindiaservices.gov.in/PublicSearch/PublicationSearch/Eregister
I think any actual long investor already assumed India and China would just make their own anyway.
Well at least Aviptidal will help save lives in India. It will moved quickly for approval and get world wide exposure. The rest of the world still is still a market for revenue though. This is still good news IMO. I hope they make enough to give every Indian citizen their own Aviptadil inhaler.
Best,
JB
We have a patent in India...
03-21-2011 MONDOBIOTECH AG granted patent in India for FORMULATION FOR AVIPTADIL
https://www.allindianpatents.com/patents/246915-formulation-for-aviptadil
06-20-2013 MondoBiotech holding AG changes name Therametrics Holding AG
“ The company changed its name from mondoBIOTECH holding AG to THERAMetrics holding AG as at 20 June 2013”
05-14-2014
RLF-100, was acquired by RELIEF THERAPEUTICS Holding SA (Swiss Exchange: RLF, OTCBB: RLFTF) from the business combination of RELIEF THERAPEUTICS Holding SA and Therametrics Holding AG in January 2016. THERAMetrics holding AG formerly was known as MondoBIOTECH holding AG.
MondoBiotech holding AG changes name Therametrics Holding AG
“ The company changed its name from mondoBIOTECH holding AG to THERAMetrics holding AG as at 20 June 2013”
Notes to the Financial Statements see 1. General Information Page 7
RLF-100, was acquired by RELIEF THERAPEUTICS Holding SA (Swiss Exchange: RLF, OTCBB: RLFTF) from the business combination of RELIEF THERAPEUTICS Holding SA and Therametrics Holding AG in January 2016. THERAMetrics holding AG formerly was known as MondoBIOTECH holding AG.
This is in the top right of the intro to this board when you view via web page
Best,
JB
02-18-2021, CI Com SA sanctioned 22,000 CHF by SER. This was the outcome of the last one and posted as a media release
https://www.ser-ag.com/dam/downloads/publication/news/media-releases/2021/20210218-e-sanction-cicom.pdf
You can see them all: https://www.ser-ag.com/en/topics/ad-hoc-publicity.html
I sure hope someone isn't posting blatantly false information about how much the last sanction was in an effort to affect RLFTF share price. That would be illegal actually and might warrant SEC action against anyone who was posting in such a manner.
Best,
JB
"I’m gravely concerned," Javitt said, speaking to variants threatening to diminish vaccine efficacy. "We should certainly celebrate the strides that we’ve made in getting a baseline level of vaccination in the population but we can’t let our vigilance down for a second."
"We need to constantly be surveilling for these new variants and we need to be developing Covid therapeutics that will rescue people who get Covid even in the face of the vaccination programs."
- Dr. Jonathan Javitt, CEO of NRx and adjunct professor at Johns Hopkins School of Medicine, told Fox News.
https://www.foxnews.com/health/lag-covid-19-vaccine-boosters-variants-therapeutics
There is no shortage of bio companies with ill equipped management. I do not think RLF/NRX would fall into that group though. They are all well seasoned and veterans of big pharma and bio companies, they know the game and have a financial interest just like we do. Say what you want but these are guys I am invested with. I got JJ, I got Ram, I got GEM... Those are my business partners and they ALL bring an area of expertise to the table. I am still not convinced Ram doesn't have a list of company's to acquire and we are just getting started on the A's of it.
There is plenty of scientific literature with empirical evidence on peptide function in mammals. A wealth of those show the benefits of VIP specifically and appear to offer potentially new treatment for a wide array of ailments. Safety & Efficacy seem to be a given at this point. The results already have been speaking for themselves. RLF/NRX are doing this without some BP "sponsor" because they are all extremely well equipped with the nuances and kid gloves that are required with the US FDA.
Best,
JB
“The stock market is a device for transferring money from the impatient to the patient”
-Warren Buffett
Worth a read: https://link.springer.com/article/10.1007/s00223-021-00820-9
"Original Research
Published: 17 May 2021
Vasoactive Intestinal Peptide Promotes Fracture Healing in Sympathectomized Mice
Liu Shi, Yang Liu, Zhengmeng Yang, Tianyi Wu, Hiu Tung Lo, Jia Xu, Jiajun Zhang, Weiping Lin, Jinfang Zhang, Lu Feng & Gang Li
Calcified Tissue International (2021)Cite this article
71 Accesses
Metricsdetails
Abstract
Vasoactive intestinal peptide (VIP) as a neuromodulator and neurotransmitter played a significant role in modulating bone homeostasis. Our previous study reported an essential role of VIP in in vitro BMSCs osteogenesis and in vivo bone defect repair. VIP was also revealed to have a promoting effect on embryonic skeletal element development. However, the role of VIP in fracture healing is not known yet. We hypothesized that the disorder of sympathetic nervous system impairs bone structure and fracture healing, whereas VIP may rescue the sympathetic inhibition effects and promote fracture healing. We employed a 6-hydroxydopamine (6-OHDA) induced sympathectomy mice model (sympathectomized mice), in which successful sympathetic inhibition was confirmed by a decreased level of norephedrine (NE) in the spleen. In the sympathectomized mice, the femoral micro-architecture, bone density and mechanical properties were all impaired compared to the vehicle control mice. The femoral fracture was created in the vehicle or sympathectomized mice. Vehicle mice were locally injected with PBS as a negative control, and the sympathectomized mice were treated with injection of PBS or VIP. VIP expression at the fracture site was significantly decreased in sympathectomized mice. The fracture healing was repressed upon 6-OHDA treatment and rescued by VIP treatment. Micro-CT examination showed that the femoral bone micro-architecture at the fracture sites and mechanical properties were all impaired. Simultaneously, the expression level of osteogenic markers OCN and OPN were reduced in sympathectomized mice compared with vehicle group. While the VIP treatment rescued the repression effects of 6-OHDA on bone remodeling and significantly promoted bone quality and mechanical properties as well as increased osteogenesis marker expression in the sympathectomized mice. VIP administration promoted bone fracture healing by inhibiting bone resorption, making it a putative new alternative treatment strategy for fracture healing."
Best,
JB
TCM, thank you for posting this. It allows for others to see what a true RLFTF investor who is just not feeling RLFTF currently would post in response. It's great to show the difference between NOTICEME,VERY CONCERNED, PANIC NOW and what you just put up about RLFTF. I for one even value dissenting viewpoints as they often help reinforce my own. You are far better than that group of cretins and I apologize if I inferred you were of the same ilk.
Best,
JB
They are just trying to "save us" Bill :) They want to tell us all day, every day because they must really care about our investments :) They must think that these FUD posts will surely increase share price since they claim to have a vested interest in it increasing.
Just think about the tenacity, here and every other platform. If it really was so concerning: they'd either have moved on by now or would use some of their apparent abundance of free time to create posts linking to studies and scientific papers etc which all show the efficacy of VIP.
Best,
JB
It looks like "WE NEED TO DO SOMETHING" and the rest of the FB Beauzos contacted SIX about "CONCERNS" about RLF. This is much ado about nothing but you can see how it was initiated. Probably 15 emails a day to SIX so they are now forced to look into and thereby forced to announce.
Think about what motivation there would be for a barrage of emails to SIX about RLF, I know I do not contact regulatory authorities about companies I own....
The BioGen approval with their inferior RCT data compared to RLF's coupled with all the steady positive RLF news buildup such as acquisitions, new regions ,new studies etc
Best,
JB
“We look forward to working with the FDA in hopes of providing critically ill patients with a new medicine that will increase their chances of recovery, enabling them to leave the hospital and return to their families significantly sooner.”
- Jonathan Javitt, MD CEO of NRx
“We look forward to working with the FDA in hopes of providing critically ill patients with a new medicine that will increase their chances of recovery, enabling them to leave the hospital and return to their families significantly sooner.” - Jonathan Javitt, MD CEO of NRx
— NRx Pharmaceuticals (@NRxPharma) June 1, 2021
Trending up, big movement will come in time
Much more instore
Most are waiting, we know what we own. The asylum seems to be under new management which drowns out and overruns many discussions. We are in a head to head trial against Remdisivar which is comsidered to be the standard of care - really big deal. I believe it too will show efficacy with statistical significance just like past trials. I wouldn't be surprised if Gilead or some other BP partnership or acquisition is announced at some point even. Speaking of acquisitions, we are still on the A's of our own list of companies to acquire- more will be coming imo. Long and strong.
Best,
JB
A great post about RLF in the EU:
https://www.reddit.com/r/ReliefTherapeutics/comments/n744kw/brparelief_therapeutics_is_almost_certainly_to_be/
All his posts are very informative and worth reading.
Best,
JB
JJ 04/27/21 Followup interview on Tech Nation
Skip to 42 Minutes in:
https://www.podomatic.com/podcasts/technation/episodes/2021-04-27T12_47_49-07_00
Best,
JB
Relief owns the Intellectual Property relating to Aviptadil and has a written contract with NRX. NRX is not some other random "other company", they are our hired contractor with whom we have entered into a profit sharing agreement with. They are not a competitor and well aware of who is in charge at the end of the day. If you disregard the "noise" about some imaginary feud or about naming trademarks or whatever the FUD purveyors spread on any given day, the drug and trials have all produced amazing results and positive news. More results will be coming since the last was entitled "...#1" Nothing to worry about IMO, just waiting.
Best,
JB
Fauci talks about Zy-es-ami today at WH COVID task force update
When you sign a contract to accomplish X and all you need from me is Y but later find out you need Z... that's on you as we have a contract for you to do X for Y
Claims of it being some massive disagreement or something else should easily be dismissed. This is how contracts work and pretty basic imo. Just the latest daily FUD talking point and nothing of significance imo. It will all work itself out in some agreeable manner regardless, waiting and holding while ignoring the daily noise.
Best,
JB
RE: I WONDER WHAT COULD END ALL THIS CONFUSION...
I will take "The most ironic thing I've read all day" for $1000 Alex.
The only way to stop disinformation is for the purveyors of such to stop; whether is be on their own accord or being forced by some entity.
Somehow, someway it will end eventually.
Eventually the road ahead becomes clear.
Consensus among the facts grows daily.
4 different trials will produce a mountain of evidence.
Yet, it's been less than a year since anything started.
Only the facts will matter in the end.
Understanding what has transpired will be the key.
Here's a good read some might find useful:
https://www.griproom.com/fun/why-your-stock-is-always-red
Best,
JB
Bleach works in vitro too...
Some of the best DD on RLFTF:
https://www.reddit.com/r/SPACs/comments/lqx2mc/brpaneurorx_relief_therapeutics_rlftf_have/
Please sticky
Best,
JB
Raghuram Selvaraju is speaking today at Sachs 2nd Annual European Healthtech Forum:
Much more is coming, Things are going to be really exciting really soon. Diamond Hands.
Best,
JB
Dr Javitt posted this on his linked in:
https://lastfuturist.com/relief-therapeutics-could-save-our-lungs-in-the-third-wave/
DD From WHINO
- Based on the below, the inputs for the primary endpoint calculation was definitely changed between the interim 28 day PR/SSRN on Feb 23rd and final 60 day PR on March 29th . The interim Feb 23rd, 28 day PR included the primary endpoint for all 196 patients (Hazard Ratio 1.53; P=.08) AND also sub-grouped to 94 patients in tertiary care (HR 1.84; P=.058). These results were calculated by controlling for 4 factors: baseline age, baseline NIAID score, baseline Respiratory Distress Ratio, and previous antiviral therapy using, the Cox Proportional Hazards Model
- The 60 day PR we got March 29th, specifically mentions controlling for ventilation status and treatment site. CLEARLY, these factors were not included in the interim 28 day calculations we got on Feb 23rd. So, they seemed to CHANGE the controlling factors between Feb 23rd and March 29th. In the 60 day data, the primary endpoint was controlled for site where as on Feb 23rd, it was not, and instead tertiary sites were broken out into a sub-group p-value (HR 1.84; P=.058).
- Controlling for ventilation status, which I take to mean use of a ventilator (mechanical/NIPPV) or not (HFNC) is a measure of 'severity'. They Feb 23rd already controlled for some form of severity using baseline NIAID scale and respiratory distress ration - so perhaps ventilation status was used to gain further precision on severity.
- Remember, NRX seems to have a good working relationship with the FDA. Endpoints have changed (60 day, no relapse, composite) even after trial completion. We have over an ENTIRE MONTH between 28 day Feb 23 and 60 day March 29th. It is HIGHLY likely NRX and FDA had some form of correspondence between Feb 23 and Mar 29. Given this, it is worth asking this question: Did NRX discuss with the FDA the change of parameters to use in the Cox model to use ventilation status and site? Controlling is OK and as FDA guidance clearly says: "Scientifically justified changes based on information external to the trial can be acceptable and sponsors are encouraged to discuss these changes with FDA." It appears controlling for treatment site falls in the category of 'scientifically justified changes...external to the trial'. I think controlling for severity using ventilation status is already covered likely wouldn't need too much FDA discussion.
- Again, let's go back to TRUST - Lavin is the GOAT and JJ has has brought many FDA approved products to market. They KNOW they data will be fully scrutinized by peers and the FDA. They would not put out these numbers unless they believed they would hold up to scrutiny. I trust these numbers are legit for the FDA to grant EUA.
- Quotes from 28 day interim SSRN:
- "The lifetable (Fig 1) depicts the prespecified primary endpoint of recovery from respiratory failure with discharge and continued survival through 28 days. When this endpoint is analyzed by the Cox Proportional Hazards Model, correcting for age, baseline NIAID, baseline severity of respiratory failure and use of previous antiviral therapy, the cumulative probability of recovery from respiratory failure, Aviptadil-treated participants were 35% (calculated as (1-(1/HR))) more likely to reach the prespecified composite endpoint than were participants treated with placebo (Hazard Ratio 1.53; P=.08). Participants treated in tertiary care hospitals demonstrated a 46% increased likelihood of reaching the composite endpoint (HR 1.84; P=.058)."
- "All analysis was by “intention to treat”; no subjects were excluded from any analyses. The primary composite endpoint of “alive to day 28 and free of respiratory failure was assessed based on (1) survival, (2) discharge from acute care hospital to either home or long term care, and (3) reaching NIAID score of 6-8. The cumulative distribution of the composite endpoint was displayed with censoring for death only at day 28 as is standard in a cumulative probability lifetable. Differences between drug and placebo were ascertained by Cox Proportional Hazards model controlling for baseline age, NIAID score, Respiratory Distress Ratio, and previous antiviral therapy. Median Time in hospital for participants who recovered from Respiratory Failure was calculated together with 95% confidence intervals."
While I have not even reached a year of holding, everything is progressing and more great news is sure to come IMO. Daily price fluctuations with RLFTF do not mean much to me since I am holding long based on the tremendous amount of DD we did months ago. All I have heard is good news (and some impatient investors), The successful 60 day results were just one of many yet to come announcements.
Best,
JB
BOOM SHOCKA LOCKA
There is also a New England Journal of Medicine article on VIP that has already been published
https://www.nejm.org/doi/full/10.1056/NEJMc2000343
Leads to Advita patent filed on 02/24/21
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020225246
RLF acquired Advita in January
https://relieftherapeutics.com/newsblog/relief-and-advita-sign-binding-term-sheet-for-relief-to-acquire-all-shares-of-advita-to-expand-scope-of-development-of-inhaled-formulation-of-aviptadil
Best,
JB
The first peer-reviewed publication on #ZYESAMI...
Nice link TheBigTicket
https://www.sciencedirect.com/science/article/pii/S1053249821020702
Here is Dr. Javitt touting it on linkedin:
"Here's the first peer-reviewed publication on #ZYESAMI. Another 93rd birthday tribute for Sami Said. This was a patient who developed clear respiratory failure from #covid?19, requiring 30 liters of nasal oxygen. Download the hi-res image and look at the "cotton-candy" appearance in the lung, especially on the right. After 24 hours of treatment, as shown in the paper, the lung is clear, the patient is down to 2 liters of oxygen, and is no longer in respiratory distress. This type of rapid recovery is not usually seen in COVID.
Of course, the plural of anecdote is not data. The motto at FDA is "in God we trust. Everybody else should please bring data." It's easy to report a case -- or multiple cases -- of dramatic improvement. Proving that such improvement is more common in drug-treated patients than in those given placebo and doing so across different hospitals, care teams, and patient populations in the middle of a pandemic is a different level of challenge."
https://www.linkedin.com/posts/jonathanjavitt_rapid-clinical-recovery-from-critical-covid-activity-6780973404049743872-M6nn